Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24 | Zendy

D. Craig Allred | Zendy; Stewart Anderson | Zendy; Soonmyung Paik | Zendy; D. Lawrence Wickerham | Zendy; Irıs D. Nagtegaal | Zendy; Sandra M. Swain | Zendy; Elefetherios P. Mamounas | Zendy; Thomas B. Julian | Zendy; Charles E. Geyer | Zendy; Joseph P. Costantino | Zendy; Stephanie R. Land | Zendy; Norman Wolmark | Zendy

Open Access

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

Author(s) -

D. Craig Allred,

Stewart Anderson,

Soonmyung Paik,

D. Lawrence Wickerham,

Irıs D. Nagtegaal,

Sandra M. Swain,

Elefetherios P. Mamounas,

Thomas B. Julian,

Charles E. Geyer,

Joseph P. Costantino,

Stephanie R. Land,

Norman Wolmark

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2010.34.0141

Subject(s) - medicine , tamoxifen , breast cancer , estrogen receptor , lumpectomy , ductal carcinoma , oncology , progesterone receptor , population , hazard ratio , cancer , immunohistochemistry , gynecology , urology , mastectomy , confidence interval , environmental health

The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-24 study demonstrated significant benefit with adjuvant tamoxifen in patients with ductal carcinoma in situ (DCIS) after lumpectomy and radiation. Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research